THCT · As filed with the SEC
THC Therapeutics cash flow statement, by fiscal year
The statement as THC Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENT OF CASH FLOWS · USD
| USD | FY2024 Year ended Jul 31, 2024 | FY2023 Year ended Jul 31, 2023 | FY2022 Year ended Jul 31, 2022 | FY2021 Year ended Jul 31, 2021 |
|---|---|---|---|---|
| Cash Flows from Operating Activities | ||||
| Net loss | — | (387,036) | — | (1,885,445) |
| Loss on change in derivative liabilities | — | — | — | 393,718 |
| Net loss | (811,562) | — | (1,518,929) | — |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||||
| Loss (gain) on change in derivative liabilities | 125,444 | (184,143) | (327,501) | — |
| Interest Expense | — | 0 | 14,682 | 277,845 |
| Stock based compensation | — | — | — | 115,692 |
| Stock-Based Compensation Expense | 222,000 | 87,170 | 836,788 | — |
| Convertible loan increase due to default | — | — | 0 | 179,960 |
| Gain on settlement of debt | — | (1,460) | — | — |
| Gain on settlement of debt | 0 | — | — | — |
| Depreciation Expense | 1,397 | 1,393 | 12,334 | 16,370 |
| Imputed interest | — | — | 0 | — |
| Interest Expense | — | — | 0 | 0 |
| Changes in operating assets and liabilities | ||||
| Increase in inventory | 0 | 25 | 805 | (830) |
| Increase (decrease) in prepaid assets | — | 39,686 | — | (4,586) |
| Decrease in prepaid assets | 970 | — | (36,070) | — |
| Increase in accounts payable and accrued expenses | 196,081 | 355,948 | 610,244 | (86,239) |
| Increase (decrease) in accounts payable related party | — | — | (11,270) | — |
| Increase (decrease) in contingent liability | — | — | 0 | 100,000 |
| Change in Accounts Payable | 82,397 | 2,985 | — | 505,038 |
| Net cash used in operating activities | (183,273) | (85,432) | (418,917) | (388,477) |
| Purchase of Silver assets | — | — | — | (152,785) |
| Purchase of silver | — | — | 0 | — |
| Net Cash from Investing Activities | — | 0 | 0 | (152,785) |
| Cash Flows provided by Financing Activities | ||||
| Proceeds from Debt Issuance | 85,985 | 36,002 | 102,881 | 91,081 |
| Payments on related party debts | — | — | — | (78,428) |
| Payments on related party advances | (527) | (50,592) | (54,562) | — |
| Stock Repurchases (Issuances) | 0 | 100,000 | 147,000 | 506,500 |
| Repurchase of common stock | — | 0 | (97,500) | — |
| Proceeds from sale of preferred stock | — | — | 0 | 300,000 |
| Proceeds from Debt Issuance | — | — | 25,000 | — |
| Repayments of convertible notes payable | — | — | 0 | — |
| Proceeds from Debt Issuance | — | 0 | — | 0 |
| Proceeds from loans | — | — | — | 0 |
| Repayments of convertible notes payable | — | — | — | (25,000) |
| Proceeds from Stock Issuance | 97,840 | — | — | — |
| Net cash provided by financing activities | 183,298 | 85,410 | 122,819 | 794,153 |
| Net decrease in Cash | — | — | (296,098) | — |
| Net decrease in Cash | 25 | (22) | — | 252,891 |
| Beginning cash balance | — | — | 296,130 | 43,239 |
| Ending cash balance | — | — | — | 296,130 |
| Beginning cash balance | 10 | 32 | 296,130 | — |
| Ending cash balance | 35 | 10 | 32 | — |
| Supplemental disclosure of cash flow information | ||||
| Derivative liability written off to additional paid in capital | — | — | 0 | — |
| Interest Expense | — | 0 | — | 0 |
| Cash paid for tax | — | 0 | — | 0 |
| Silver used to settle debt | — | 152,785 | — | — |
| Interest Expense | 0 | — | — | — |
| Income Tax Expense | 0 | — | — | — |
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||
| Derivative Liability written off to additional paid in capital | — | — | — | 128,001 |
| Shares issued for the conversion of notes payable | — | — | — | 101,500 |
| Silver used to settle debt | 0 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.